For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Teleflex (TFX) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy DevelopmentLiam Kelly - Chairman, President & CEOJohn Deren - EVP & CFOPatrick Wood - Managing DirectorJayson Bedford - Managing Director - Medical TechnologyAnthony Petrone - Managing DirectorRichard Newitter - Managing Director Conference Call Participants Michael Sarcone - AnalystVikramjeet Chopra - AnalystMatthew O'Brien - AnalystShagun Singh Chadha - Analy ...

Teleflex (TFX) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.88 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.04%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.86 per share when it actually produced earnings of $3.89, delivering a surprise of 0.78%.Over the last four quarters, the co ...

Teleflex (TFX) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy DevelopmentLiam Kelly - Chairman, President & CEOJohn Deren - EVP & CFOPatrick Wood - Managing DirectorJayson Bedford - Managing Director - Medical TechnologyAnthony Petrone - Managing DirectorRichard Newitter - Managing Director Conference Call Participants Michael Sarcone - AnalystVikramjeet Chopra - AnalystMatthew O'Brien - AnalystShagun Singh Chadha - Analy ...

Teleflex (TFX) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Teleflex First Quarter twenty twenty five Earnings Conference Call. At this time, all participants have been placed in a listen only mode. At the end of the company's prepared remarks, we will conduct a question and answer session. Please note that this conference call is being recorded, and we will be available on the company's website for replay shortly. Now I will turn the call ov ...

Teleflex Incorporated First Quarter 2025 Earnings Conference Call 5/1/2025 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on May 1, 2025 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Today's Speakers Liam ...

FOR IMMEDIATE RELEASE May 1, 2025 Exhibit 99.1 First quarter financial summary 2025 guidance summary "Our performance for the first quarter was in line with our expectations" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "Were it not for the impact of tariffs enacted since the issuance of our previous guidance, we project that our full-year results for 2025 would fall within our previously stated guidance ranges. We are evaluating strategies to mitigate our exposure to tariffs ...

Financial Performance - Company reported net revenues of $700.7 million for the first quarter of 2025, a decrease of 5.0% compared to $737.8 million in the prior year period [8][34] - GAAP diluted earnings per share (EPS) from continuing operations was $2.07, compared to $0.33 in the prior year period [8][46] - Adjusted diluted EPS from continuing operations was $2.91, down from $3.21 in the prior year period [8][46] Revenue by Segment - In the Americas, net revenue was $475.7 million, down 3.7% from $494.0 million [5][34] - EMEA segment reported net revenue of $151.2 million, a decrease of 5.3% from $159.6 million [5][34] - Asia segment saw a decline of 12.4%, with revenues of $73.8 million compared to $84.2 million [5][34] Revenue by Product Category - Vascular Access category reported revenues of $182.4 million, a slight increase of 0.6% from $181.4 million [7][34] - Interventional category revenues increased by 2.1% to $137.5 million from $134.7 million [7][34] - Anesthesia revenues decreased by 10.1% to $86.6 million from $96.4 million [9][34] Guidance and Outlook - Company raised its full-year 2025 revenue growth outlook on a GAAP basis to a range of 1.28% to 2.28% [10][11] - Adjusted diluted EPS guidance for 2025 was lowered to a range of $13.20 to $13.60, down from $13.95 to $14.35 [11][12] - Expected impact from tariffs in 2025 is approximately $55 million, which will be recorded in cost of goods sold [8][11] Strategic Initiatives - Company is evaluating strategies to mitigate exposure to tariffs and remains focused on executing its plan for the year [3] - Plans to separate Teleflex into two independent publicly traded companies, with significant third-party interest in acquiring NewCo [3]

Company Overview - Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] Product Portfolio - Teleflex is home to several trusted brands such as Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] Upcoming Events - Management of Teleflex will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 1:40 p.m. (PT) [1] - A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website [1]

WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical w ...